secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amneal Pharmaceuticals, Inc. (AMRX)
CIK:        0001723128
Form:       8-K
Filed at:   2026-08-03T20:28:16+00:00
Accession:  0001628280-26-051900
Event type: debt
Sentiment:  positive
Materiality: 0.55
Item codes: 1.01, 2.03
LLM model:  deepseek-v4-flash:cloud@v2

Amneal reprices $2.084B term loan, cuts interest margin by 50 bps, saving ~$12M annually
--------------------------------------------------------------------------------

- Reduced interest rate margin by 50 bps to 1.50% (base rate) and 2.50% (SOFR) on $2.084B term loans.
- Converted $2.039B existing term loans on cashless basis; added $45.2M new term loan to repay non-converted loans.
- Maturity unchanged at August 1, 2032; no prepayment premium for repricing after February 3, 2027.
- Estimated annualized cash interest savings of approximately $12 million based on outstanding borrowings.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1723128/000162828026051900/0001628280-26-051900-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1723128/000162828026051900/amrx-20260803.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-051900

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer